Inflammasome Therapeutics

Name

Inflammasome Therapeutics

Legal name

Inflammasome Therapeutics, Inc.

Website

https://inflam.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals (Ophthalmology and Neurodegenerative Disease Therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Inflammasome inhibitors
• Ocular therapeutics
• Degenerative disease treatments
• Clinical stage biopharmaceuticals
• Kamuvudine drug platform

Headquarters

HQ city

Newton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company developing proprietary drugs K8 and K9 for degenerative diseases. Revenue will come from drug commercialization upon FDA approval for geographic atrophy, diabetic macular edema, thyroid eye disease, and neurological conditions including ALS, Alzheimer's, Parkinson's, and multiple sclerosis.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Inflammasome Therapeutics is a clinical-stage biopharmaceutical company developing proprietary Kamuvudine drug candidates — K8 (a bioerodible ocular implant) and K9 (an oral compound) — that inhibit inflammasome activation to treat degenerative diseases including geographic atrophy, diabetic macular edema, thyroid eye disease, Alzheimer's, Parkinson's, multiple sclerosis, and ALS. The Kamuvudines are derivatives of FDA-approved NRTIs designed to retain anti-inflammasome activity while eliminating mitochondrial toxicity.

Product overview

Inflammasome Therapeutics is developing a portfolio of inflammasome inhibitor therapies based on its proprietary Kamuvudine platform. The company has two lead products: K8 (dual inflammasome inhibitor ocular implant) in Phase I/II for geographic atrophy, and K9 (oral dual inflammasome inhibitor) in Phase I for thyroid eye disease, diabetic macular edema, and ALS. Both products inhibit inflammasome activation and the associated inflammatory cascade (IL-1β, IL-18, IL-6, TNF-α, interferon-γ). The company is also developing programs for Alzheimer's disease, multiple sclerosis, and Parkinson's disease.

Differentiator

Problem solved

Functional benefit

Brands

• K8: Dual inflammasome inhibitor implant for treating geographic atrophy (GA). A powerful inflammasome inhibitor developed as a tiny, bioerodible, injectable implant injected into the vitreous for sustained release directly to the back of the eye.
• K9
• Kamuvudines

Products and services

• K8 Ocular Implant Dual inflammasome inhibitor (Kamuvudine derivative) delivered as a tiny bioerodible injectable vitreous implant providing sustained drug release directly to the back of the eye while avoiding systemic exposure. Currently in Phase I/II trials for geographic atrophy (GA), the advanced form of dry AMD.
• K9 Oral

Quantifiable outcome

• K8 reduced GA lesion area growth by more than 50% after 3 months in Phase I/II clinical trial
• +2 more outcomes

Segments7 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and major.

• Sean M. Healey & AMG Center for ALS at Massachusetts General HospitalcoreStrategic or Co-development Partner · 13 November 2025Collaboration to develop and advance oral Kamuvudine-9 (K9) into early Phase 1b/2a clinical trials under the MyMatch program, which matches ALS patients to experimental therapies based on biomarkers. The partnership aims to evaluate the drug's potential in reducing biomarkers associated with ALS progression.
• Boehringer IngelheimmajorStrategic or Co-development Partner · 20 September 2019Partnership to develop novel therapies for patients with retinal diseases. Boehringer Ingelheim collaboration focused on advancing inflammasome inhibitor therapies.
• University of Kentucky Research FoundationcoreOEM/ Whitelabel/ Licensing PartnerExclusive worldwide license to patents arising from Dr. Ambati's laboratory covering NRTIs and Kamuvudines for treatment of dry AMD, GA, Parkinson's, Alzheimer's, MS, rheumatoid arthritis, and diabetes. 13 patents granted in US and other countries.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Annexon Biosciences: Annexon is developing classical complement pathway inhibitors for geographic atrophy and several neurodegenerative diseases including ALS and Huntington's disease. Directly comparable to Inflammasome in targeting complement/inflammatory pathways across ophthalmology and neurology.
• Apellis Pharmaceuticals: Apellis developed Syfovre, the first FDA-approved treatment for geographic atrophy (GA). Direct competitor to Inflammasome's K8 in the GA market with a complement inhibitor (pegcetacoplan) approach rather than inflammasome inhibition.
• Astellas Pharma (Iveric Bio): Astellas acquired Iveric Bio and gained Izervay (avacincaptad pegol), the second FDA-approved GA therapy. Direct competitor to Inflammasome's K8 in geographic atrophy with a C5 complement inhibitor mechanism.
• Kodiak Sciences: Kodiak Sciences develops sustained-release intravitreal therapeutics for retinal diseases including AMD and diabetic macular edema. Directly comparable to Inflammasome's K8 ocular implant approach using sustained-release ocular drug delivery.

Emerging players

• ZyVersa Therapeutics: ZyVersa is developing inflammasome-targeting therapeutics including NLRP3 inhibitors. Direct overlap with Inflammasome's inflammasome inhibition approach for inflammatory and degenerative diseases, though earlier stage.
• Olatec Therapeutics: Olatec is developing a portfolio of NLRP3 inflammasome inhibitors for inflammatory and autoimmune diseases. Direct mechanistic overlap with Inflammasome's Kamuvudine platform in targeting the NLRP3 inflammasome pathway.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the leading anti-VEGF therapy for wet AMD and diabetic macular edema. Comparable to Inflammasome's K9 oral alternative for DME, and broader competitor in retinal disease therapeutics.
• Roche (Genentech): Roche markets Lucentis and Vabysmo for wet AMD and DME, and is developing therapies for Alzheimer's disease. Large incumbent with overlapping ophthalmology and neurology franchises that Inflammasome is targeting with K8/K9.
• Biogen: Biogen markets Leqembi for Alzheimer's disease and Tysabri for multiple sclerosis, and is developing ALS therapies. Comparable in targeting the same neurodegenerative indications (AD, MS, ALS) that Inflammasome is pursuing with K9.

Others

• Alnylam Pharmaceuticals: Alnylam pioneered RNAi therapeutics, including Onpattro which uses similar NRTI-adjacent chemistry to NRTIs/Kamuvudines. Comparable as a nucleic acid-based drug development company, though targets different mechanisms (RNAi vs inflammasome inhibition).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inflammasome-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inflammasome Therapeutics